Seres Therapeutics Inc. logo

Seres Therapeutics Inc.

MCRB | NASDAQ
Chart Builder DCF Calculator
$4.08
+$0.01 (+0.25%)
Sep 22, 2026, 11:09 AM ET · Market open

Market Data

Market Cap
$39.41M
Enterprise Value
$80.46M
Beta
0.22
Average Volume
78.76K
Shares Outstanding (Diluted)
9.64M
Shares Change YoY
10.3%
Institutional Ownership
24.07%
Exchange
NASDAQ
ISIN
US81750R2013

Price Performance

Price Change 1M
-9.3%
Price Change 3M
-42.3%
Price Change 6M
-55.5%
Price Change YTD
-73.1%
Price Change 1Y
-75.4%
Price Change 3Y
-92.2%
Price Change 5Y
-97.1%
1M CAGR (ann.)
-16.4%
1Y CAGR (ann.)
-77.4%
5Y CAGR (ann.)
-49.0%
All-Time CAGR
-38.9%

Valuation

PE Ratio
-1.69
Forward PE
N/A
PEG Ratio
0.00
Forward PEG
-0.04
PS Ratio
20.93
Forward PS
144.10
PB Ratio
1.14
P/FCF Ratio
-0.58
P/Adj. FCF Ratio
-0.50
P/OCF Ratio
-0.77
EV/Sales
42.73
EV/EBIT
-1.67
EV/EBITDA
-1.81
EV/FCF
-1.19
Earnings Yield
-59.2%
FCF Yield
-171.7%
Adj. FCF Yield
-199.4%

Financial Health

Net Cash
$15.59M
Total Debt
$56.64M
Cash & Short-Term Investments
$15.59M
Total Assets
$101.59M
Current Ratio
2.11
Quick Ratio
2.11
Debt / Equity Ratio
1.64
Debt / EBITDA
-1.28
Debt / FCF
-0.84
OCF / Debt
-1.19
Interest Coverage
0.00
Altman Z-Score
-14.55
Piotroski F-Score
2

Margins & Profitability

Gross Profit Margin
82.6%
Operating Profit Margin
-4462.8%
EBITDA Margin
-2354.9%
Net Profit Margin
-1192.9%
FCF Margin
-3592.9%
Adj. FCF Margin
-4174.6%
SBC / Revenue
487.8%
SBC Impact (per share)
-16.2%

Returns

Return on Assets
-22.1%
Return on Equity
-60.3%
Return on Invested Capital
-90.0%
Return on Capital Employed
-103.0%
Return on Tangible Assets
-22.1%

Historical Growth (CAGR)

Revenue CAGR 3Y
-75.7%
Revenue CAGR 5Y
-42.5%
Revenue CAGR 10Y
-10.5%
EPS CAGR 3Y
93.8%
EPS CAGR 5Y
35.4%
EPS CAGR 10Y
13.7%
FCF CAGR 3Y
56.1%
FCF CAGR 5Y
4.0%
FCF CAGR 10Y
-2.1%

Analyst Forecasts

Analyst Rating
Buy
Analyst Count
18
EPS Growth Next 3Y
-85.7%
Revenue Growth Next 3Y
-33.8%
Earnings Date
Nov 3, 2026
EPS Estimate (next Q)
-$1
EPS Growth Est (next Q)
-206.9%
Revenue Est (next Q)
$6.35M
Revenue Growth Est (next Q)
1709.1%

Fair Value Estimates

Graham Number
N/A
Graham Upside
N/A
Lynch Fair Value
N/A
Lynch Upside
N/A
Price Target
$12
Price Target Upside
194.8%

Cash Flow

Operating Cash Flow
$-67.62M
Free Cash Flow
$-67.66M
Adj. Free Cash Flow
$-78.61M
FCF Per Share
-$5.32
OCF Per Share
-$5.31
OCF/S Ratio
-2722.1%

Income Statement

Revenue
$1.88M
Gross Profit
$1.56M
Operating Income
$-84.03M
EBITDA
$-44.34M
Net Income
$-22.46M
EPS (Diluted)
-$2.41
Revenue / Employee
$28.53K
Profit / Employee
$-340.35K
Employees
66

© 2026 bestshares.com. All rights reserved.